In a report released yesterday, Michael Ryskin from Bank of America Securities reiterated a Buy rating on Danaher (DHR – Research Report), with a price target of $230.00.
Michael Ryskin has given his Buy rating due to a combination of factors that highlight Danaher’s strong performance and strategic positioning. The company reported first-quarter results that surpassed expectations, particularly in the Bioprocessing and CPHD respiratory segments, which underscores its resilience in a challenging market environment. Danaher has maintained its fiscal year 2025 sales guidance and increased its bioprocessing growth forecast, reflecting confidence in its operational capabilities and market demand.
Moreover, Danaher has demonstrated its ability to mitigate potential headwinds, such as tariffs, through strategic measures like surcharges and supply-chain management. The company has also identified cost actions that provide additional flexibility if macroeconomic conditions worsen. These factors, combined with a stable demand in key markets like Pharma and China, reinforce the positive outlook for Danaher’s stock, justifying the Buy rating with a price objective of $230.
In another report released yesterday, Jefferies also maintained a Buy rating on the stock with a $230.00 price target.
Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DHR in relation to earlier this year.